clinical trial · NCT05236868
A Study of JNJ-42847922 (Seltorexant) in Healthy Participants
Janssen Research & Development, LLC·phase1·completed·n = 10
HealthySeltorexant
brief summary
The purpose of this study is to determine the absolute bioavailability of seltorexant in healthy participants following a single oral dose of seltorexant and an intravenous (IV) infusion dose of 14C-seltorexant.
started
Feb 3, 2022
primary completion
Mar 1, 2022
completion
Mar 1, 2022
last updated
Apr 27, 2025
official title
An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-42847922 (Seltorexant) Administered as Oral Tablet and an Intravenous Microdose of 14C-seltorexant in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol